Finland is exceptionally advanced in utilising user-friendly, high-quality drug information in everyday clinical work. This is largely due to Medbase and its partners, who provide critical information for healthcare professionals. Together with private equity company Vaaka Partners, Medbase aims to extend its unique expertise further into Europe.

Strategic partnership

Vaaka Partners selected Medbase for its impressive scientific expertise and significant end-user impact. Medbase enhances clinical decision making by providing evidence-based, user-friendly drug information across all relevant areas of pharmacotherapy. As the leading Nordic provider of drug information, Medbase’s solutions are trusted by healthcare professionals in Finland and internationally for clinical drug therapy.

‘Medbase’s world-class databases help patients use fewer medications that are not right for them. It’s rewarding to bring this expertise globally, as many doctors still lack pragmatic tools to safeguard their prescribing in progressive countries. Medbase has the potential to improve patient care worldwide,’ says Ville Koskenvuo, partner at Vaaka Partners.

‘With Vaaka Partners’ expertise, we can expand our reach in Europe and continue improving clinical decision making,’ says Dr. Kari Laine, founder and Chief Medical Officer of Medbase. ‘We share the same vision and values with Vaaka, which has enabled us to build mutual trust,’ adds Dr. Laine.

Strong medical expertise

Following the investment, Medbase’s Board of Directors now includes:

• Prof. Juha Tuominen (former CEO of Helsinki University Hospital HUS)
• Katrin Wiemann (former General Manager of ifap, part of CompuGroup Medical)
• Kari Lappalainen (CEO of Solutos)
• Ville Koskenvuo (Partner at Vaaka Partners, founding investor and former Chairman of Blueprint Genetics)
• Panu Vuorela (Partner at Vaaka Partners)

‘The drug information provided by Medbase is of high scientific quality and necessary for good clinical practice. I am motivated to support Medbase in launching new databases and enabling wider access to this seamless service across Europe,’ says Prof. Juha Tuominen, former CEO of HUS.

Future outlook

Unintended but predictable adverse drug reactions are a growing global issue, leading to increased mortality, morbidity and healthcare costs. The complexity of available treatment options necessitates decision support systems that guide and remind doctors of best treatment practices. Medbase’s extensive product portfolio offers much-needed assistance to clinical practitioners across Europe.

Learn more about Vaaka Partners here.